AIP
CTKB icon

Ameritas Investment Partners’s Cytek Biosciences CTKB Stock Holding History

Ameritas Investment Partners’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.9K Hold
9,823
– – ﹤0.01% 2177
2025
Q4 		$49.6K Hold
9,823
– – ﹤0.01% 2118
2025
Q3 		$34.1K Sell
9,823
-2,219
-18% -$8.33K ﹤0.01% 2410
2025
Q2 		$40.9K Hold
12,042
– – ﹤0.01% 2315
2025
Q1 		$48.3K Hold
12,042
– – ﹤0.01% 2121
2024
Q4 		$78.2K Hold
12,042
– – ﹤0.01% 1927
2024
Q3 		$66.7K Hold
12,042
– – ﹤0.01% 2025
2024
Q2 		$67.2K Hold
12,042
– – ﹤0.01% 1972
2024
Q1 		$80.8K Hold
12,042
– – ﹤0.01% 1870
2023
Q4 		$110K Hold
12,042
– – ﹤0.01% 1668
2023
Q3 		$66.5K Buy
12,042
+2,033
+20% +$16.3K ﹤0.01% 1927
2023
Q2 		$85.5K Buy
10,009
+1,445
+17% +$13K ﹤0.01% 1703
2023
Q1 		$78.7K Hold
8,564
– – ﹤0.01% 1687
2022
Q4 		$93.8K Hold
8,564
– – ﹤0.01% 1647
2022
Q3 		$126K Hold
8,564
– – 0.01% 1333
2022
Q2 		$91K Buy
8,564
+997
+13% +$9.92K ﹤0.01% 1577
2022
Q1 		$82K Buy
7,567
+6,336
+515% +$85.6K ﹤0.01% 1763
2021
Q4 		$20K Hold
1,231
– – ﹤0.01% 2640
2021
Q3 		$26K Buy
+1,231
New +$29K ﹤0.01% 2554

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ameritas Investment Partners's CTKB Position: Q1 2026 in Review

Ameritas Investment Partners held its Cytek Biosciences (CTKB) position steady in Q1 2026 at 9,823 shares worth $42.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2177.

Ameritas Investment Partners first reported a position in CTKB in Q3 2021 and has held it in 19 quarters since. The position peaked at $126K in Q3 2022. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Ameritas Investment Partners held 9,823 shares of Cytek Biosciences worth $42.9K as of Q1 2026.
  • Ameritas Investment Partners left its Cytek Biosciences share count unchanged in Q1 2026.
  • Cytek Biosciences made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2177 holding.
  • Ameritas Investment Partners first reported a position in Cytek Biosciences in Q3 2021 and has held it in 19 quarters since.
  • Ameritas Investment Partners's Cytek Biosciences position peaked at $126K in Q3 2022.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.